MASCC Conference moved to June 2021, BMX-001 High grade glioma abstract accepted, Title: Cognitive Outcomes Of Phase 1 Trial Of Novel Metalloporphyrin Radioprotectant And Radiosensitizer In Newly Diagnosed High Grade Glioma Patients
Link to ASCO 2020 Abstract for Clinical Trials In Progress, BMX-001 in patients with HGG: https://lnkd.in/ehHTZfa
BioMimetix is awarded a Phase IIb bridge award from the National Cancer Institute to support ongoing Phase 2 randomized trial studying BMX-001 in combination with Temozolomide and Radiation Therapy in patients with High Grade Glioma,
BioMimetix announces they received Fast Track Designation for the investigation of BMX-001 in combination with RT and TMZ for the treatment of patients with newly diagnosed high grade glioma to demonstrate a clinically meaningful and statistically robust improvement in overall
Fast Track is a process designed to promote the development and speed up the review of drugs for serious conditions with an unmet medical need. This helps lead to faster availability of new treatment options for patients.
BMX-001 is currently being studied in a randomized Phase 2 trial of HGG patients receiving radiation therapy and temozolomide.
BioMimetix’s novel drug, BMX-001, is granted Orphan Designation by the FDA for treatment of glioma
BioMimetix was selected by the NIH to showcase in the Innovation Zone at BIO International Convention in Philadelphia, PA, June 3-6, 2019.
BioMimetix awarded grant by the National Institutes of Health to fund work in patients with Multiple Brain Metastases.